Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Apr;87(4):483-7. doi: 10.1038/clpt.2009.313. Epub 2010 Feb 24.

Interleukin-6 as a therapeutic target in candidate inflammatory diseases.

Author information

1
Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki-City, Japan. norichan@wakayama-med.ac.jp

Abstract

Interleukin (IL)-6 is a multifunctional cytokine that regulates immune response, inflammation, and hematopoiesis. Although IL-6 plays several important physiological roles, deregulated overproduction of IL-6 causes various clinical symptoms and abnormalities in laboratory test results. Overproduction of IL-6 has been shown to underlie a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), systemic-onset juvenile idiopathic arthritis (soJIA), and Castleman's disease, as well as malignancies such as multiple myeloma and mesothelioma. Blocking of IL-6 signaling may be therapeutic in diseases characterized by pathological IL-6 overproduction. This review provides an overview of IL-6 as a therapeutic target in candidate inflammatory diseases.

PMID:
20182422
DOI:
10.1038/clpt.2009.313
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center